XML 22 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Net revenues $ 16,659 $ 16,887 $ 18,271
Cost of sales 8,933 9,351 9,975
Gross profit 7,726 7,537 8,296
Research and development expenses 997 1,010 1,213
Selling and marketing expenses 2,498 2,614 2,916
General and administrative expenses 1,173 1,192 1,298
Intangible assets impairments 1,502 1,639 1,991
Goodwill impairment 4,628   3,027
Other asset impairments, restructuring and other items 479 423 987
Legal settlements and loss contingencies 60 1,178 (1,208)
Other income (40) (76) (291)
Operating (loss) income (3,572) (443) (1,637)
Financial expenses, net 834 822 959
Income (loss) before income taxes (4,406) (1,265) (2,596)
Income taxes (benefit) (168) (278) (195)
Share in (profits) losses of associated companies, net (138) 13 71
Net income (loss) (4,099) (1,000) (2,472)
Net loss attributable to non-controlling interests (109) (2) (322)
Net income (loss) attributable to Teva (3,990) (999) (2,150)
Accrued dividends on preferred shares     249
Net income (loss) attributable to ordinary shareholders $ (3,990) $ (999) $ (2,399)
Earnings (loss) per share attributable to ordinary shareholders:      
Basic $ (3.64) $ (0.91) $ (2.35)
Diluted $ (3.64) $ (0.91) $ (2.35)
Weighted average number of shares (in millions):      
Basic 1,095 1,091 1,021
Diluted 1,095 1,091 1,021